Discovery of potent and selective sirtuin 2 (SIRT2) inhibitors using a fragment-based approach

Journal of Medicinal Chemistry

Volumn 57, Issue 20, 2014, Pages 8340-8357

  Cui, Huaqing ^a   Kamal, Zeeshan ^a   Ai, Teng ^a   Xu, Yanli ^a   More, Swati S ^a   Wilson, Daniel J ^a   Chen, Liqiang ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (NAPHTHALEN 2 YLAMINO)BENZAMIDE; 3 (NAPHTHALEN 2 YLOXY)BENZAMIDE; 4 (NAPHTHALEN 1 YLAMINO)BENZAMIDE; 4 (NAPHTHALEN 1 YLOXY)BENZAMIDE; 4 (NAPHTHALEN 1 YLTHIO)BENZAMIDE; 4 (NAPHTHALEN 2 YLAMINO)BENZAMIDE; 4 (NAPHTHALEN 2 YLOXY)BENZAMIDE; 4 (NAPHTHALEN 2 YLTHIO)BENZAMIDE; 5 (NAPHTHALEN 2 YLAMINO)NICOTINAMIDE; 5 (NAPHTHALEN 2 YLOXY)NICOTINAMIDE; 5 [(5 BENZAMIDONAPHTHALEN 2 YL)OXY]NICOTINAMIDE; 5 [[5 (3 NITROBENZAMIDO)NAPHTHALEN 2 YL]OXY]NICOTINAMIDE; 5 [[5 (4 METHYLBENZAMIDO)NAPHTHALEN 2 YL]OXY]NICOTINAMIDE; 6 (NAPHTHALEN 1 YLAMINO)NICOTINAMIDE; 6 (NAPHTHALEN 1 YLOXY)NICOTINAMIDE; 6 (NAPHTHALEN 1 YLTHIO)NICOTINAMIDE; 6 (NAPHTHALEN 2 YLAMINO)NICOTINAMIDE; 6 (NAPHTHALEN 2 YLOXY)NICOTINAMIDE; ALPHA TUBULIN; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; HISTONE DEACETYLASE INHIBITOR; NAPHTHALENE DERIVATIVE; NICOTINAMIDE; SIRTUIN 1; SIRTUIN 2 INHIBITOR; SIRTUIN 3; SULFONIC ACID DERIVATIVE; SURAMIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; ENZYME INHIBITOR; LIGAND; SIRT2 PROTEIN, HUMAN; SIRTUIN 2;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CHEMICAL ANALYSIS; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG ACETYLATION; DRUG BINDING; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; NONHUMAN; STRUCTURE ACTIVITY RELATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DOG; DRUG DEVELOPMENT; DRUG EFFECTS; MCF 7 CELL LINE; MDCK CELL LINE; PROCEDURES;

ANIMALS; DOGS; DRUG DESIGN; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; HUMANS; LIGANDS; MADIN DARBY CANINE KIDNEY CELLS; MCF-7 CELLS; MOLECULAR STRUCTURE; NIACINAMIDE; SIRTUIN 2; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONIC ACIDS; SURAMIN;

EID: 84908363759     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm500777s     Document Type: Article

References (62)

1. Blander, G.; Guarente, L. The Sir2 family of protein deacetylases Annu. Rev. Biochem. 2004, 73, 417-435
2. Houtkooper, R. H.; Pirinen, E.; Auwerx, J. Sirtuins as regulators of metabolism and healthspan Nat. Rev. Mol. Cell Biol. 2012, 13, 225-238
3. Smith, B. C.; Hallows, W. C.; Denu, J. M. Mechanisms and molecular probes of sirtuins Chem. Biol. 2008, 15, 1002-1013
4. Sauve, A. A. Sirtuin chemical mechanisms Biochim. Biophys. Acta 2010, 1804, 1591-1603
5. He, B.; Du, J.; Lin, H. Thiosuccinyl peptides as Sirt5-specific inhibitors J. Am. Chem. Soc. 2012, 134, 1922-1925
6. Hu, J.; He, B.; Bhargava, S.; Lin, H. A fluorogenic assay for screening Sirt6 modulators Org. Biomol. Chem. 2013, 11, 5213-5216
7. Tervo, A. J.; Kyrylenko, S.; Niskanen, P.; Salminen, A.; Leppanen, J.; Nyronen, T. H.; Jarvinen, T.; Poso, A. An in silico approach to discovering novel inhibitors of human sirtuin type 2 J. Med. Chem. 2004, 47, 6292-6298
8. Peng, C.; Lu, Z.; Xie, Z.; Cheng, Z.; Chen, Y.; Tan, M.; Luo, H.; Zhang, Y.; He, W.; Yang, K.; Zwaans, B. M.; Tishkoff, D.; Ho, L.; Lombard, D.; He, T. C.; Dai, J.; Verdin, E.; Ye, Y.; Zhao, Y. The first identification of lysine malonylation substrates and its regulatory enzyme Mol. Cell. Proteomics 2011, 10 M111.012658
9. Du, J.; Zhou, Y.; Su, X.; Yu, J. J.; Khan, S.; Jiang, H.; Kim, J.; Woo, J.; Kim, J. H.; Choi, B. H.; He, B.; Chen, W.; Zhang, S.; Cerione, R. A.; Auwerx, J.; Hao, Q.; Lin, H. Sirt5 is a NAD-dependent protein lysine demalonylase and desuccinylase Science 2011, 334, 806-809
10. Barber, M. F.; Michishita-Kioi, E.; Xi, Y.; Tasselli, L.; Kioi, M.; Moqtaderi, Z.; Tennen, R. I.; Paredes, S.; Young, N. L.; Chen, K.; Struhl, K.; Garcia, B. A.; Gozani, O.; Li, W.; Chua, K. F. SIRT7 links H3K18 deacetylation to maintenance of oncogenic transformation Nature 2012, 487, 114-118
11. Webster, B. R.; Lu, Z.; Sack, M. N.; Scott, I. The role of sirtuins in modulating redox stressors Free Radical Biol. Med. 2012, 52, 281-290
12. Knight, J. R.; Milner, J. SIRT1, metabolism and cancer Curr. Opin. Oncol. 2012, 24, 68-75
13. Donmez, G.; Outeiro, T. F. SIRT1 and SIRT2: Emerging targets in neurodegeneration EMBO Mol. Med. 2013, 5, 344-352
14. Outeiro, T. F.; Kontopoulos, E.; Altmann, S. M.; Kufareva, I.; Strathearn, K. E.; Amore, A. M.; Volk, C. B.; Maxwell, M. M.; Rochet, J. C.; McLean, P. J.; Young, A. B.; Abagyan, R.; Feany, M. B.; Hyman, B. T.; Kazantsev, A. G. Sirtuin 2 inhibitors rescue α-synuclein-mediated toxicity in models of Parkinson's disease Science 2007, 317, 516-519
15. Eskandarian, H. A.; Impens, F.; Nahori, M. A.; Soubigou, G.; Coppee, J. Y.; Cossart, P.; Hamon, M. A. A role for SIRT2-dependent histone H3K18 deacetylation in bacterial infection Science 2013, 341 1238858
16. Yuan, H.; Su, L.; Chen, W. Y. The emerging and diverse roles of sirtuins in cancer: A clinical perspective Oncol. Targets Ther. 2013, 6, 1399-1416
17. Alhazzazi, T. Y.; Kamarajan, P.; Verdin, E.; Kapila, Y. L. SIRT3 and cancer: Tumor promoter or suppressor? Biochim. Biophys. Acta 2011, 1816, 80-88
18. Cen, Y. Sirtuins inhibitors: The approach to affinity and selectivity Biochim. Biophys. Acta 2010, 1804, 1635-1644
19. Chen, L. Medicinal chemistry of sirtuin inhibitors Curr. Med. Chem. 2011, 18, 1936-1946
20. Grozinger, C. M.; Chao, E. D.; Blackwell, H. E.; Moazed, D.; Schreiber, S. L. Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening J. Biol. Chem. 2001, 276, 38837-38843
21. Mai, A.; Massa, S.; Lavu, S.; Pezzi, R.; Simeoni, S.; Ragno, R.; Mariotti, F. R.; Chiani, F.; Camilloni, G.; Sinclair, D. A. Design, synthesis, and biological evaluation of sirtinol analogues as class III histone/protein deacetylase (sirtuin) inhibitors J. Med. Chem. 2005, 48, 7789-7795
22. Rotili, D.; Tarantino, D.; Nebbioso, A.; Paolini, C.; Huidobro, C.; Lara, E.; Mellini, P.; Lenoci, A.; Pezzi, R.; Botta, G.; Lahtela-Kakkonen, M.; Poso, A.; Steinkuhler, C.; Gallinari, P.; De Maria, R.; Fraga, M.; Esteller, M.; Altucci, L.; Mai, A. Discovery of salermide-related sirtuin inhibitors: Binding mode studies and antiproliferative effects in cancer cells including cancer stem cells J. Med. Chem. 2012, 55, 10937-10947
23. Heltweg, B.; Gatbonton, T.; Schuler, A. D.; Posakony, J.; Li, H.; Goehle, S.; Kollipara, R.; Depinho, R. A.; Gu, Y.; Simon, J. A.; Bedalov, A. Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes Cancer Res. 2006, 66, 4368-4377
24. Medda, F.; Russell, R. J.; Higgins, M.; McCarthy, A. R.; Campbell, J.; Slawin, A. M. Z.; Lane, D. P.; Lain, S.; Westwood, N. J. Novel cambinol analogues as sirtuin inhibitors: Synthesis, biological evaluation, and rationalization of activity J. Med. Chem. 2009, 52, 2673-2682
25. Mahajan, S. S.; Scian, M.; Sripathy, S.; Posakony, J.; Lao, U.; Loe, T. K.; Leko, V.; Thalhofer, A.; Schuler, A. D.; Bedalov, A.; Simon, J. A. Development of Pyrazolone and Isoxazol-5-one Cambinol Analogues as Sirtuin Inhibitors J. Med. Chem. 2014, 57, 3283-3294
26. Bedalov, A.; Gatbonton, T.; Irvine, W. P.; Gottschling, D. E.; Simon, J. A. Identification of a small molecule inhibitor of Sir2p Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 15113-15118
27. Neugebauer, R. C.; Uchiechowska, U.; Meier, R.; Hruby, H.; Valkov, V.; Verdin, E.; Sippl, W.; Jung, M. Structure-activity studies on splitomicin derivatives as sirtuin inhibitors and computational prediction of binding mode J. Med. Chem. 2008, 51, 1203-1213
28. Posakony, J.; Hirao, M.; Stevens, S.; Simon, J. A.; Bedalov, A. Inhibitors of Sir2: Evaluation of splitomicin analogues J. Med. Chem. 2004, 47, 2635-2644
29. Freitag, M.; Schemies, J.; Larsen, T.; El Gaghlab, K.; Schulz, F.; Rumpf, T.; Jung, M.; Link, A. Synthesis and biological activity of splitomicin analogues targeted at human NAD(+)-dependent histone deacetylases (sirtuins) Bioorg. Med. Chem. 2011, 19, 3669-3677
30. Napper, A. D.; Hixon, J.; McDonagh, T.; Keavey, K.; Pons, J. F.; Barker, J.; Yau, W. T.; Amouzegh, P.; Flegg, A.; Hamelin, E.; Thomas, R. J.; Kates, M.; Jones, S.; Navia, M. A.; Saunders, J. O.; DiStefano, P. S.; Curtis, R. Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1 J. Med. Chem. 2005, 48, 8045-8054
31. Smith, M. R.; Syed, A.; Lukacsovich, T.; Purcell, J.; Barbaro, B. A.; Worthge, S. A.; Wei, S. R.; Pollio, G.; Magnoni, L.; Scali, C.; Massai, L.; Franceschini, D.; Camarri, M.; Gianfriddo, M.; Diodato, E.; Thomas, R.; Gokce, O.; Tabrizi, S. J.; Caricasole, A.; Landwehrmeyer, B.; Menalled, L.; Murphy, C.; Ramboz, S.; Luthi-Carter, R.; Westerberg, G.; Marsh, J. L. A potent and selective sirtuin 1 inhibitor alleviates pathology in multiple animal and cell models of Huntington's disease Hum. Mol. Genet. 2014, 10.1093/hmg/ddu010
32. Schuetz, A.; Min, J.; Antoshenko, T.; Wang, C. L.; Allali-Hassani, A.; Dong, A.; Loppnau, P.; Vedadi, M.; Bochkarev, A.; Sternglanz, R.; Plotnikov, A. N. Structural basis of inhibition of the human NAD+-dependent deacetylase SIRT5 by suramin Structure 2007, 15, 377-389
33. Trapp, J.; Meier, R.; Hongwiset, D.; Kassack, M. U.; Sippl, W.; Jung, M. Structure-activity studies on suramin analogues as inhibitors of NAD+-dependent histone deacetylases (sirtuins) ChemMedChem 2007, 2, 1419-1431
34. Spires-Jones, T. L.; Fox, L. M.; Rozkalne, A.; Pitstick, R.; Carlson, G. A.; Kazantsev, A. G. Inhibition of Sirtuin 2 with Sulfobenzoic Acid Derivative AK1 is Non-Toxic and Potentially Neuroprotective in a Mouse Model of Frontotemporal Dementia Front. Pharmacol. 2012, 3, 42
35. Taylor, D. M.; Balabadra, U.; Xiang, Z.; Woodman, B.; Meade, S.; Amore, A.; Maxwell, M. M.; Reeves, S.; Bates, G. P.; Luthi-Carter, R.; Lowden, P. A.; Kazantsev, A. G. A brain-permeable small molecule reduces neuronal cholesterol by inhibiting activity of sirtuin 2 deacetylase ACS Chem. Biol. 2011, 6, 540-546
36. Luthi-Carter, R.; Taylor, D. M.; Pallos, J.; Lambert, E.; Amore, A.; Parker, A.; Moffitt, H.; Smith, D. L.; Runne, H.; Gokce, O.; Kuhn, A.; Xiang, Z.; Maxwell, M. M.; Reeves, S. A.; Bates, G. P.; Neri, C.; Thompson, L. M.; Marsh, J. L.; Kazantsev, A. G. SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 7927-7932
37. Choi, S. H.; Quinti, L.; Kazantsev, A. G.; Silverman, R. B. 3-(N -Arylsulfamoyl)benzamides, inhibitors of human sirtuin type 2 (SIRT2) Bioorg. Med. Chem. Lett. 2012, 22, 2789-2793
38. Khanfar, M. A.; Quinti, L.; Wang, H.; Choi, S. H.; Kazantsev, A. G.; Silverman, R. B. Development and characterization of 3-(benzylsulfonamido)benzamides as potent and selective SIRT2 inhibitors Eur. J. Med. Chem. 2014, 76, 414-426
39. Trapp, J.; Jochum, A.; Meier, R.; Saunders, L.; Marshall, B.; Kunick, C.; Verdin, E.; Goekjian, P.; Sippl, W.; Jung, M. Adenosine mimetics as inhibitors of NAD+-dependent histone deacetylases, from kinase to sirtuin inhibition J. Med. Chem. 2006, 49, 7307-7316
40. Lain, S.; Hollick, J. J.; Campbell, J.; Staples, O. D.; Higgins, M.; Aoubala, M.; McCarthy, A.; Appleyard, V.; Murray, K. E.; Baker, L.; Thompson, A.; Mathers, J.; Holland, S. J.; Stark, M. J.; Pass, G.; Woods, J.; Lane, D. P.; Westwood, N. J. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator Cancer Cell 2008, 13, 454-463
41. McCarthy, A. R.; Pirrie, L.; Hollick, J. J.; Ronseaux, S.; Campbell, J.; Higgins, M.; Staples, O. D.; Tran, F.; Slawin, A. M. Z.; Lain, S.; Westwood, N. J. Synthesis and biological characterisation of sirtuin inhibitors based on the tenovins Bioorg. Med. Chem. 2012, 20, 1779-1793
42. Morimoto, J.; Hayashi, Y.; Suga, H. Discovery of Macrocyclic Peptides Armed with a Mechanism-Based Warhead: Isoform-Selective Inhibition of Human Deacetylase SIRT2 Angew. Chem., Int. Ed. 2012, 51, 3423-3427
43. Friden-Saxin, M.; Seifert, T.; Landergren, M. R.; Suuronen, T.; Lahtela-Kakkonen, M.; Jarho, E. M.; Luthman, K. Synthesis and Evaluation of Substituted Chroman-4-one and Chromone Derivatives as Sirtuin 2-Selective Inhibitors J. Med. Chem. 2012, 55, 7104-7113
44. Suzuki, T.; Khan, M. N.; Sawada, H.; Imai, E.; Itoh, Y.; Yamatsuta, K.; Tokuda, N.; Takeuchi, J.; Seko, T.; Nakagawa, H.; Miyata, N. Design, synthesis, and biological activity of a novel series of human sirtuin-2-selective inhibitors J. Med. Chem. 2012, 55, 5760-5773
45. Disch, J. S.; Evindar, G.; Chiu, C. H.; Blum, C. A.; Dai, H.; Jin, L.; Schuman, E.; Lind, K. E.; Belyanskaya, S. L.; Deng, J.; Coppo, F.; Aquilani, L.; Graybill, T. L.; Cuozzo, J. W.; Lavu, S.; Mao, C.; Vlasuk, G. P.; Perni, R. B. Discovery of thieno[3,2- d ]pyrimidine-6-carboxamides as potent inhibitors of SIRT1, SIRT2, and SIRT3 J. Med. Chem. 2013, 56, 3666-3679
46. Hajduk, P. J.; Greer, J. A decade of fragment-based drug design: Strategic advances and lessons learned Nat. Rev. Drug Discovery 2007, 6, 211-219
47. Rees, D. C.; Congreve, M.; Murray, C. W.; Carr, R. Fragment-based lead discovery Nat. Rev. Drug Discovery 2004, 3, 660-672
48. North, B. J.; Marshall, B. L.; Borra, M. T.; Denu, J. M.; Verdin, E. The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase Mol. Cell 2003, 11, 437-444
49. Hubbert, C.; Guardiola, A.; Shao, R.; Kawaguchi, Y.; Ito, A.; Nixon, A.; Yoshida, M.; Wang, X. F.; Yao, T. P. HDAC6 is a microtubule-associated deacetylase Nature 2002, 417, 455-458
50. Finnin, M. S.; Donigian, J. R.; Pavletich, N. P. Structure of the histone deacetylase SIRT2 Nat. Struct. Biol. 2001, 8, 621-625
51. Avalos, J. L.; Bever, K. M.; Wolberger, C. Mechanism of sirtuin inhibition by nicotinamide: Altering the NAD+ cosubstrate specificity of a Sir2 enzyme Mol. Cell 2005, 17, 855-868
52. Moniot, S.; Schutkowski, M.; Steegborn, C. Crystal structure analysis of human Sirt2 and its ADP-ribose complex J. Struct. Biol. 2013, 182, 136-143
53. Ullmann, H.; Meis, S.; Hongwiset, D.; Marzian, C.; Wiese, M.; Nickel, P.; Communi, D.; Boeynaems, J. M.; Wolf, C.; Hausmann, R.; Schmalzing, G.; Kassack, M. U. Synthesis and structure-activity relationships of suramin-derived P2Y11 receptor antagonists with nanomolar potency J. Med. Chem. 2005, 48, 7040-7048
54. Wolfe, J. P.; Buchwald, S. L. Scope and limitations of the Pd/BINAP-catalyzed amination of aryl bromides J. Org. Chem. 2000, 65, 1144-1157
55. Burgos, C. H.; Barder, T. E.; Huang, X.; Buchwald, S. L. Significantly improved method for the Pd-catalyzed coupling of phenols with aryl halides: Understanding ligand effects Angew. Chem., Int. Ed. 2006, 45, 4321-4326
56. Itoh, T.; Mase, T. A general palladium-catalyzed coupling of aryl bromides/triflates and thiols Org. Lett. 2004, 6, 4587-4590
57. Maiti, D.; Buchwald, S. L. Cu-catalyzed arylation of phenols: Synthesis of sterically hindered and heteroaryl diaryl ethers J. Org. Chem. 2010, 75, 1791-1794
58. Jung, N.; Brase, S. Diaryl ether and diaryl thioether syntheses on solid supports via copper(I)-mediated coupling J. Comb. Chem. 2009, 11, 47-71
59. Di Santo, R.; Costi, R.; Cuzzucoli Crucitti, G.; Pescatori, L.; Rosi, F.; Scipione, L.; Celona, D.; Vertechy, M.; Ghirardi, O.; Piovesan, P.; Marzi, M.; Caccia, S.; Guiso, G.; Giorgi, F.; Minetti, P. Design, synthesis, and structure-activity relationship of N -arylnaphthylamine derivatives as amyloid aggregation inhibitors J. Med. Chem. 2012, 55, 8538-8548
60. More, S. S.; Vartak, A. P.; Vince, R. The butter flavorant, diacetyl, exacerbates β-amyloid cytotoxicity Chem. Res. Toxicol. 2012, 25, 2083-2091
61. Schrödinger, release 2014-1: Maestro, version 9.7; Prime, version 3.5; LigPrep, version 2.9; Glide, version 6.2; Schrödinger, LLC: New York, 2014.
62. The PyMOL Molecular Graphics System, version 1.5.0.4; Schrödinger, LLC: New York.